Paradigm Biopharmaceuticals says tests show its injectable drug eases the pain of osteoarthritis in dogs. Read more in our health stocks wrap.
The company said that as part of a study, iPPS had provided durable improvements in pain, joint function, and cartilage volume, compared to a placebo.
PAR’s randomised study showed that when osteoarthritic dogs were administered iPPS over 26 weeks, they showed stabilised disease progression at week 8 and week 26.
For the latest health news, sign up here for free Stockhead daily newsletters
The 26-week timepoint in the canine model is equivalent to approximately three years in humans, highlighting the durability of positive iPPS treatment effects on osteoarthritis pain, joint structure and function.
This canine study provides consistent evidence, and mirrors the improvements shown in clinical outcomes previously reported from the phase 2 PARA_OA_008 Day 168 results.
“Paradigm will use these canine data in our ongoing discussions with the regulators,” said CEO, Paul Rennie.
MORE FROM STOCKHEAD: Zelira’s drug ‘better than Big Pharma’s’| ASX biotechs breaking through | Diabetes drugs can help weight loss
New US deal for HeraMED
HeraMED (ASX:HMD) – a medical data and technology company in the maternity care area – has signed a strategic enterprise deal with Fond, a US-based global SaaS platform that consolidates employee rewards and recognition processes into an easy-to-use solution.
Fond enables employees and managers to recognise each other, redeem rewards, and access exclusive corporate discounts for their corporate members.
The deal will enable Fond to access HeraMED solutions across all of its clients.
One of the first customers is an unnamed California-based, global social media company with more than 7000 employees.
Separately, an agreement was also signed with Entrustia Health (part of Refresh Health) to provide the obstetrics and gynaecology medical support.
This is HeraMED’s first agreement in the employer segment which represents an important sales channel going forward.
Visit Stockhead, where ASX small caps are big deals
Imugene doses first patient
Imugene (ASX:IMU) has announced the first patient has been dosed in the IMPRINTER study, a clinical trial to evaluate the safety and efficacy of Imugene’s PD1-Vaxx in patients with non-small cell lung cancer (NSCLC).
The study is to determine the safety, efficacy, and optimal dose of PD1-Vaxx in combination with atezolizumab as therapy.
The study will be conducted at sites in the US and Australia.
This content first appeared on stockhead.com.au
SUBSCRIBE
Get the latest Stockhead news delivered free to your inbox. Click here